---
authors:
- Shaughnessy, Allen
category: Clinical Review
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/37843954/
file_path: 2023/10/cholesterol-reducer-evolocumab-associated-with-a-nonsignific.md
issue: '4'
keywords:
- Humans
- Cardiovascular Diseases
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Antibodies, Monoclonal, Humanized
- Treatment Outcome
- Anticholesteremic Agents
- Cholesterol
last_updated: '2025-07-30'
mesh_terms:
- Humans
- Antibodies, Monoclonal, Humanized
- Anticholesteremic Agents
- Cholesterol
- Cardiovascular Diseases
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Treatment Outcome
original_format: PubMed
pages: 406-407
patient_population: Adults
peer_reviewed: true
pmid: '37843954'
processed_date: '2025-07-30'
publication_date: '2023-10-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-09'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Cholesterol-Reducer Evolocumab Associated With a Nonsignificant Increase in
  Cardiovascular Mortality.
topics:
- Family Medicine
volume: '108'
publication_types: &id001
- Journal Article
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '37843954'
  title: Cholesterol-Reducer Evolocumab Associated With a Nonsignificant Increase
    in Cardiovascular Mortality.
  authors:
  - last_name: Shaughnessy
    fore_name: Allen
    initials: F
    affiliation: Tufts University, Boston, Mass.
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '108'
    issue: '4'
  publication_info:
    year: '2023'
    month: '10'
    full_date: '2023-10-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Humans
    major_topic: false
  - descriptor: Antibodies, Monoclonal, Humanized
    major_topic: false
    qualifiers:
    - qualifier: adverse effects
      major_topic: false
  - descriptor: Anticholesteremic Agents
    major_topic: true
    qualifiers:
    - qualifier: adverse effects
      major_topic: false
  - descriptor: Cholesterol
    major_topic: false
  - descriptor: Cardiovascular Diseases
    major_topic: true
  - descriptor: Hydroxymethylglutaryl-CoA Reductase Inhibitors
    major_topic: true
  - descriptor: Treatment Outcome
    major_topic: false
  publication_types: *id001
related_articles:
- pmid: '37843954'
  title: Cholesterol-Reducer Evolocumab Associated With a Nonsignificant Increase
    in Cardiovascular Mortality.
  authors:
  - name: Shaughnessy F
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2023 Oct
- pmid: '32605806'
  title: First national registry on the effectiveness and safety of evolocumab in
    clinical practice in patients attended in cardiology in Spain. The RETOSS-CARDIO
    study.
  authors:
  - name: Barrios V
    authtype: Author
    clusterid: ''
  - name: Escobar C
    authtype: Author
    clusterid: ''
  - name: Arrarte V
    authtype: Author
    clusterid: ''
  - name: García E
    authtype: Author
    clusterid: ''
  - name: Fernández MR
    authtype: Author
    clusterid: ''
  - name: Rincón LM
    authtype: Author
    clusterid: ''
  - name: Roldán C
    authtype: Author
    clusterid: ''
  source: Clin Investig Arterioscler
  pubdate: 2020 Nov-Dec
- pmid: '37068131'
  title: Letter by Zhou et al Regarding Article, "Long-Term Evolocumab in Patients
    With Established Atherosclerotic Cardiovascular Disease".
  authors:
  - name: Zhou X
    authtype: Author
    clusterid: ''
  - name: Sun P
    authtype: Author
    clusterid: ''
  - name: Yang Q
    authtype: Author
    clusterid: ''
  source: Circulation
  pubdate: 2023 Apr 18
- pmid: '33941192'
  title: 'Effects of evolocumab in individuals with type 2 diabetes with and without
    atherogenic dyslipidemia: An analysis from BANTING and BERSON.'
  authors:
  - name: Lorenzatti AJ
    authtype: Author
    clusterid: ''
  - name: Monsalvo ML
    authtype: Author
    clusterid: ''
  - name: López JAG
    authtype: Author
    clusterid: ''
  - name: Wang H
    authtype: Author
    clusterid: ''
  - name: Rosenson RS
    authtype: Author
    clusterid: ''
  source: Cardiovasc Diabetol
  pubdate: 2021 Apr 30
- pmid: '28304224'
  title: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
  authors:
  - name: Sabatine MS
    authtype: Author
    clusterid: ''
  - name: Giugliano RP
    authtype: Author
    clusterid: ''
  - name: Keech AC
    authtype: Author
    clusterid: ''
  - name: Honarpour N
    authtype: Author
    clusterid: ''
  - name: Wiviott SD
    authtype: Author
    clusterid: ''
  - name: Murphy SA
    authtype: Author
    clusterid: ''
  - name: Kuder JF
    authtype: Author
    clusterid: ''
  - name: Wang H
    authtype: Author
    clusterid: ''
  - name: Liu T
    authtype: Author
    clusterid: ''
  - name: Wasserman SM
    authtype: Author
    clusterid: ''
  - name: Sever PS
    authtype: Author
    clusterid: ''
  - name: Pedersen TR
    authtype: Author
    clusterid: ''
  - name: FOURIER Steering Committee and Investigators
    authtype: CollectiveName
    clusterid: ''
  source: N Engl J Med
  pubdate: 2017 May 4
---

# Cholesterol-Reducer Evolocumab Associated With a Nonsignificant Increase in Cardiovascular Mortality.

**Authors:** Shaughnessy, Allen

**Published in:** American family physician | Vol. 108, No. 4 | 2023-10-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/37843954/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Family Medicine

## MeSH Terms

Humans, Antibodies, Monoclonal, Humanized, Anticholesteremic Agents, Cholesterol, Cardiovascular Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Treatment Outcome

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/37843954/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
